North America Cardiometabolic Diseases Market
The North America Cardiometabolic Diseases Market size was valued at US$ 32,912.1 Mn in 2021 and is projected to reach US$ 43,583.6 Mn by 2028, growing at a CAGR of 4.1% during 2021 - 2028.
Report Coverage
- Type: Cardiovascular disease, Type 2 diabetes, Hypertension, Obesity
- Treatment: ACE Inhibitors, Diuretics, Glucophage
- Dosage: Tablet, Injection
- Route of Administration: Oral, Intravenous
- End Users: Hospital, Clinic, Homecare Settings
US$ 32,912.1 Mn
Market size in 2021
US$ 43,583.6 Mn
Market Size by 2028
4.1%
CAGR, 2021 - 2028
2022-2028
Forecast Period
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Cardiometabolic Diseases Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Cardiometabolic Diseases Market Regional Analysis
6.2 North America Cardiometabolic Diseases Market Revenue 2019-2028 (US$ Million)
6.3 North America Cardiometabolic Diseases Market Forecast Analysis
7. North America Cardiometabolic Diseases Market Analysis – by Type
7.1 Cardiovascular disease
- 7.1.1 Overview
- 7.1.2 Cardiovascular disease: North America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.2 Type 2 diabetes
- 7.2.1 Overview
- 7.2.2 Type 2 diabetes: North America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.3 Hypertension
- 7.3.1 Overview
- 7.3.2 Hypertension: North America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.4 Obesity
- 7.4.1 Overview
- 7.4.2 Obesity: North America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
8. North America Cardiometabolic Diseases Market Analysis – by Treatment
8.1 ACE Inhibitors
- 8.1.1 Overview
- 8.1.2 ACE Inhibitors: North America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.2 Diuretics
- 8.2.1 Overview
- 8.2.2 Diuretics: North America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.3 Glucophage
- 8.3.1 Overview
- 8.3.2 Glucophage: North America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
9. North America Cardiometabolic Diseases Market Analysis – by Dosage
9.1 Tablet
- 9.1.1 Overview
- 9.1.2 Tablet: North America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.2 Injection
- 9.2.1 Overview
- 9.2.2 Injection: North America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
10. North America Cardiometabolic Diseases Market Analysis – by Route of Administration
10.1 Oral
- 10.1.1 Overview
- 10.1.2 Oral: North America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
10.2 Intravenous
- 10.2.1 Overview
- 10.2.2 Intravenous: North America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
11. North America Cardiometabolic Diseases Market – North America Analysis
11.1 Overview
11.2 North America- 11.2.1 North America Cardiometabolic Diseases Market Breakdown, by Key Country, 2022 and 2028 (%)
- 11.2.1.1 North America Cardiometabolic Diseases Market – Revenue and Forecast Analysis – by Country
- 11.2.1.1 US: North America Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.1.1 US: North America Cardiometabolic Diseases Market Breakdown, by Type
- 11.2.1.1.2 US: North America Cardiometabolic Diseases Market Breakdown, by Treatment
- 11.2.1.1.3 US: North America Cardiometabolic Diseases Market Breakdown, by Dosage
- 11.2.1.1.4 US: North America Cardiometabolic Diseases Market Breakdown, by Route of Administration
- 11.2.1.2 Canada: North America Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.2.1 Canada: North America Cardiometabolic Diseases Market Breakdown, by Type
- 11.2.1.2.2 Canada: North America Cardiometabolic Diseases Market Breakdown, by Treatment
- 11.2.1.2.3 Canada: North America Cardiometabolic Diseases Market Breakdown, by Dosage
- 11.2.1.2.4 Canada: North America Cardiometabolic Diseases Market Breakdown, by Route of Administration
- 11.2.1.3 Mexico : North America Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.3.1 Mexico : North America Cardiometabolic Diseases Market Breakdown, by Type
- 11.2.1.3.2 Mexico : North America Cardiometabolic Diseases Market Breakdown, by Treatment
- 11.2.1.3.3 Mexico : North America Cardiometabolic Diseases Market Breakdown, by Dosage
- 11.2.1.3.4 Mexico : North America Cardiometabolic Diseases Market Breakdown, by Route of Administration
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Eli Lilly and Company.
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Bayer AG
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Arrowhead Pharmaceuticals, Inc
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Novartis AG
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Boehringer Ingelheim International Gmbh
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Novo Nordisk A/S
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 AstraZeneca
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Alnylam Pharmaceuticals, Inc.
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Cardax, Inc.
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Kowa Company, Ltd.
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations
Access the Full N Market Report
Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.
